FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor–Positive, HER2-Negative Metastatic Breast Cancer
Julia A. Beaver(Center for Drug Evaluation and Research), Patricia Cortazar(Center for Drug Evaluation and Research), Jeanne Fourie Zirkelbach(United States Food and Drug Administration), Liang Zhao(United States Food and Drug Administration), Minerva Hughes(Center for Drug Evaluation and Research), Amna Ibrahim(Beni-Suef University), Shenghui Tang(United States Food and Drug Administration), Richard Pazdur(United States Food and Drug Administration), Todd R. Palmby(University of North Carolina at Chapel Hill), Paul G. Kluetz(United States Food and Drug Administration), Laleh Amiri‐Kordestani(United States Food and Drug Administration), Geoffrey Kim(United States Food and Drug Administration), Joyce Z. Crich(Center for Drug Evaluation and Research), Wei Chen(Army Medical University), Qi Liu(United States Food and Drug Administration), Jingyu Yu(Center for Drug Evaluation and Research), Amy Tilley(Center for Drug Evaluation and Research), Rosane Charlab, Rajeshwari Sridhara(Center for Drug Evaluation and Research), Erik Bloomquist(Center for Drug Evaluation and Research)
Cited by 377
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
|The Oncologist|2007|1.4k
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
|Clinical Cancer Research|2019|1.2k